Observational Registry of the Treatment of Glanzmann's Thrombasthenia
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
This observational registry is conducted in Europe, Asia, Africa and the United States of
 America (USA).

 The purpose of the registry is to evaluate the efficacy and safety of activated recombinant
 human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during
 invasive procedures/surgery in patients with Glanzmann's thrombasthenia (GT) with past or
 present refractoriness to platelet transfusions. Attention will be directed towards
 complications related to thrombo-embolic events and concomitant medications especially
 antifibrinolytics.
Inclusion Criteria:

 -  Patients with congenital GT defined as patients with lifelong bleeding tendency
 characterised by impaired or absent platelet aggregation, impaired clot retraction and
 prolonged bleeding time or prolonged platelet function analyser closure time. The
 patient has normal platelet counts and platelet morphology. Optional diagnosis
 criteria are quantitative or qualitative evaluation of GP (Glycoprotein) IIb/IIIa
 receptor including flow cytometry and identification of gene defects

 -  Signed informed consent by the patient or next of kin or legally acceptable
 representative to collect data on treatment of a given bleeding episode or surgical
 event as specified in the protocol. If informed consent is provided by the next of kin
 or legally acceptable representative, consent must also be obtained from the patient
 as soon as he/she is able to do so. Informed consent must be obtained before entry of
 data into the registry

 Exclusion Criteria:

 -  Patients with acquired thrombasthenic states caused by autoimmune disorders (acute or
 chronic) or drugs